# US 12,415,850 B2 · Compositions and methods for regulating production of an antibody like protein and ribonucleic acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,415,850 B2
- Document ID: US12415850B2
- Status: Granted
- Kind: B2
- Application number: 18/432,991
- Filed: 2024-02-05
- Published: 2025-02-13
- Granted: 2025-09-16
- Earliest claimed: 2023-08-09
- Assignees: Wyvern Pharmaceuticals Inc.
- Applicants: Wyvern Pharmaceuticals Inc.
- Inventors: Bradley G. Thompson
- Web page: https://patentgrep.com/patent/US12415850B2

## CPC

- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- A61P 31/16: for influenza or rhinoviruses
- C07K 14/005: from viruses
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/86: Viral vectors
- A61K 39/42: viral
- A61K 2039/53: {DNA (RNA) vaccination}
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2750/00043: viral genome or elements thereof as genetic vector
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure relates to one or more agents, therapies, treatments, and methods of use of the agents and/or therapies and/or treatments for producing an antibody like protein (ALP) and one or more sequences of miRNA that are complementary to the mRNA of a target, viral-specific protein or proteins. Embodiments of the present disclosure can be used as a therapy or a treatment for a subject that has a condition whereby the production of the APL and decreased production of a target, viral-specific protein or proteins may be of therapeutic benefit.

## Claims

### Claim 1

A method of treating a subject with a condition, the method comprising a step of administering to the subject a therapeutic dose of a composition that comprises a recombinant plasmid (RP) with a sequence of nucleotides that comprise a start region, an end region and an insert positioned between the start region and the end region, wherein the insert encodes for production of an antibody-like protein (ALP) that is bindable with a surface protein of an influenza virus and a further sequence of micro-interfering ribonucleic acid (miRNA) that binds to and causes degradation of messenger ribonucleic acid (mRNA) that encodes for a target, viral protein of the influenza virus,
wherein the sequence of nucleotides of the insert comprises:
i) a sequence that comprises SEQ ID No: 1, and
ii) the further sequence that comprises SEQ ID No: 2.

### Claim 2 (depends on 1)

The method of claim 1, wherein the condition is an infection of the influenza virus.